Document is current
Any future updates will be listed below
-
Authors
D’Aquila, Veronica
Biliotti, Elisa
D’Abramo, Alessandra
Kontogiannis, Dimitra
Faraglia, Francesca
Vita, Serena
Taibi, Chiara
Petrone, Ada
Garbuglia, Anna Rosa
D’Offizi, Gianpiero
Geretti, Anna Maria
Nicastri, Emanuele
-
Funding
Funding for this research was provided by:
Italiam Ministry of Health (Linea 1 and Linea 2 Progetto 5b)
- License Information
-
More Information
Article History
Received: 17 February 2026
Accepted: 29 June 2026
First Online: 7 July 2026
Declarations
:
: The study was approved by the Ethics Committee of the Lazio Area 4 (n. 44-2025). Written informed consent was obtained from all participants, with assistance from translators when necessary. The study was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: EB, GdO: Personal fees from Abbvie and Gilead and research funding (to institution) from Gilead, for unrelated work. CT: Personal fees from Abbvie and Gilead, for unrelated work. AMG: Personal fees from Abbott, Gilead, Roche and GSK; research funding (to institution) from Gilead, Roche and ViiV for unrelated work. EN: Personal fees from Roche, Gilead, Valneva and Takeda and research funding (to institution) from Takeda, for unrelated work. VdA, ADA, DK, FF, SV, AP, ARG: None.
